tetano
Editor, Senior Moderator
Expert Rev Mol Diagn
. 2024 Oct 4:1-12.
doi: 10.1080/14737159.2024.2408745. Online ahead of print. Multiplex molecular assays for the laboratory-based and point-of-care diagnosis of infections caused by seasonal influenza, COVID-19, and RSV
Alexander Domnich[SUP] 1 [/SUP], Elvira Massaro[SUP] 2 [/SUP], Giancarlo Icardi[SUP] 1 2 3 [/SUP], Andrea Orsi[SUP] 1 2 3 [/SUP]
Affiliations
Introduction: SARS-CoV-2, seasonal influenza, and respiratory syncytial virus (RSV) are major causes of acute respiratory infections in all age groups and responsible for an enormous socio-economic burden. The recently coined term 'tripledemic' describes co-circulation of these three viruses, a novel epidemiological paradigm that poses profound public health implications.
Areas covered: Real-time reverse transcription polymerase chain reaction (RT-PCR) is now considered the reference method for the diagnosis of SARS-CoV-2, influenza, and RSV infections. Syndromic-based multiplex RT-PCR panels that simultaneously detect several respiratory viruses have become increasingly common. This review explores available molecular diagnostics (MDx) platforms for the diagnosis of SARS-CoV-2, influenza, and RSV in the same biological sample. Within some limitations of the published validation and diagnostic accuracy studies, both laboratory-based and point-of-care multiplex panels proved highly performant in identifying SARS-CoV-2, influenza A, influenza B, and RSV. Improved operational efficiency and faster turnaround times make these assays potentially cost-effective or even cost-saving.
Expert opinion: The adoption of multiplex MDx assays for the contemporary detection of SARS-CoV-2, influenza, RSV, and other respiratory pathogens will likely increase in the next few years. To maximize the clinical usefulness and cost-effectiveness of these assays, locally issued guidelines and protocols on their implementation should be adopted.
Keywords: COVID-19; Influenza; RSV; RT-PCR; SARS-CoV-2; molecular testing; point-of-care systems; respiratory syncytial virus.
. 2024 Oct 4:1-12.
doi: 10.1080/14737159.2024.2408745. Online ahead of print. Multiplex molecular assays for the laboratory-based and point-of-care diagnosis of infections caused by seasonal influenza, COVID-19, and RSV
Alexander Domnich[SUP] 1 [/SUP], Elvira Massaro[SUP] 2 [/SUP], Giancarlo Icardi[SUP] 1 2 3 [/SUP], Andrea Orsi[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 39364620
- DOI: 10.1080/14737159.2024.2408745
Introduction: SARS-CoV-2, seasonal influenza, and respiratory syncytial virus (RSV) are major causes of acute respiratory infections in all age groups and responsible for an enormous socio-economic burden. The recently coined term 'tripledemic' describes co-circulation of these three viruses, a novel epidemiological paradigm that poses profound public health implications.
Areas covered: Real-time reverse transcription polymerase chain reaction (RT-PCR) is now considered the reference method for the diagnosis of SARS-CoV-2, influenza, and RSV infections. Syndromic-based multiplex RT-PCR panels that simultaneously detect several respiratory viruses have become increasingly common. This review explores available molecular diagnostics (MDx) platforms for the diagnosis of SARS-CoV-2, influenza, and RSV in the same biological sample. Within some limitations of the published validation and diagnostic accuracy studies, both laboratory-based and point-of-care multiplex panels proved highly performant in identifying SARS-CoV-2, influenza A, influenza B, and RSV. Improved operational efficiency and faster turnaround times make these assays potentially cost-effective or even cost-saving.
Expert opinion: The adoption of multiplex MDx assays for the contemporary detection of SARS-CoV-2, influenza, RSV, and other respiratory pathogens will likely increase in the next few years. To maximize the clinical usefulness and cost-effectiveness of these assays, locally issued guidelines and protocols on their implementation should be adopted.
Keywords: COVID-19; Influenza; RSV; RT-PCR; SARS-CoV-2; molecular testing; point-of-care systems; respiratory syncytial virus.